Eye tumors / Uveal melanoma

ATOM

Adjuvant tebentafusp (IMCgp100) versus observation in HLA-A*02:01positive patients following definitive treatment of high-risk uveal melanoma: an EORTC randomized phase III study;(ATOM Trial)

Open at Paris since : 27/11/2024
Target : Adult
Phase : Phase III

Trial description

The primary objective is to prospectively assess whether adjuvant;treatment with tebentafusp improves recurrence-free survival (RFS) as;compared to observation.;The secondary objectives are as follows:;À to prospectively assess whether adjuvant tebentafusp improves;overall survival (OS) as compared to observation,;À to prospectively assess safety of adjuvant tebentafusp.

Url of the trial

Main investigator

MANUEL RODRIGUES

Médecin

Contact